Avita Medical

227 articles with Avita Medical

• AVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

  2/3/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021

• AVITA Medical to Announce Fiscal Second Quarter 2021 Financial Results

  1/28/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal second quarter 2021 financial results after the market closes on Thursday, February 11,

• AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results

  1/12/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2020.

• AVITA Medical to Present at the J.P. Morgan 39th Annual Healthcare Conference

  12/28/2020

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. Eastern Time. A live, audio-only webcast of the presentat

• RECELL® System Data Presented at American Burn Association Fall Regional Burn Conferences

  12/15/2020

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the presentation of RECELL® System data recently presented at the Northeast Regional Burn Conference and Southern Regional Burn Conference of the American Burn Association.

• AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America

  6/29/2020

  AVITA Medical Limited ACN 058 466 523 is pleased to announce that the scheme of arrangement to effect the redomiciliation of the Company and its subsidiaries from Australia to the United States of America has been implemented.

• AVITA Medical Limited Proposed Redomiciliation to the United States of America - Results of Scheme Meeting

  6/15/2020

  AVITA Medical Limited ACN 058 466 523 is pleased to announce that shareholders voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America, under which AVITA Therapeutics, Inc., a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.

• AVITA Medical Limited Proposed Redomiciliation to the United States of America - Chair’s Address to Scheme Meeting

  6/14/2020

  In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited ACN 058 466 523 is pleased to provide a copy of the Chair’s address for the Scheme Meeting being held virtually at 9.00am, being Monday, 15 June 2020.

• AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo

  6/1/2020

  AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.

• AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference

  5/21/2020

  AVITA Medical Limited ( Company ) (ASX:AVH) (NASDAQ:RCEL) today announced that management will present virtually at the upcoming Jefferies Virtual Health Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT. Authorised for release by the Chief Financial Officer of AVITA Medical Limited. ABOUT AVITA MEDICAL LIMITED AVITA Medical is a regenerative medicine company with a techno

• AVITA Medical Limited Proposed Redomiciliation to the United States of America – Registration of Scheme Booklet with ASIC and Financial Reporting Relief Granted by ASIC

  5/11/2020

  AVITA Medical Limited is pleased to announce that the Australian Securities and Investments Commission has registered the scheme booklet in relation to the proposed scheme of arrangement under which AVITA Therapeutics, Inc., a newly-formed company incorporated in Delaware in the United States of America, will become the parent company of the Company and its subsidiaries for the purposes of effecting a redomiciliation of the Avita Group from Australia to the United States of America.

• AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update

  4/29/2020

  AVITA Medical Limited, a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the fiscal third quarter ended 31 March 2020 in its Appendix 4C - Quarterly Cash Flow Report filed with the Australian Securities Exchange.

• AVITA Medical Announces Intention to Redomicile to the United States of America

  4/20/2020

  AVITA Medical Limited ( Company ) (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today its intention to redomicile the Company and its subsidiaries ( Avita Group ) from A

• RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online

  4/2/2020

  Abstracts Highlighting RECELL Clinical and Health Economic Benefits Included in Journal of Burn Care & Research Supplement

• First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction

  3/3/2020

  Study to enroll a minimum of 65 patients across the United States to evaluate safety and effectiveness of treatment of acute, non-burn skin injuries

• AVITA Medical to Attend the 2020 BTIG Healthcare Conference

  3/3/2020

  AVITA Medical, a global regenerative medicine company, announced that management will attend the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from Wednesday, March 18, 2020 through Thursday, March 19, 2020 at The Cliff Lodge in Snowbird, Utah.

• AVITA Medical Half-Year Financial Report for Fiscal 2020

  2/19/2020

  AVITA Medical Limited announced that it filed with the Australian Securities Exchange its Appendix 4D – Half-Year Report for the six month period ended 31 December 2019.

• AVITA Medical to Present at the Cowen 40th Annual Health Care Conference

  2/11/2020

  AVITA Medical, a global regenerative medicine company, announced that management will present at the Cowen 40th Annual Health Care Conference in Boston.

• AVITA Medical Reports Second Quarter Fiscal 2020 Financial Results and Company Update

  1/31/2020

  AVITA Medical Limited, a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, reported financial results for the fiscal second quarter ended 31 December 2019 in its Appendix 4C - Quarterly Cash Flow Report filed with the Australian Securities Exchange.

• AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System for Vitiligo

  12/29/2019

  AVITA Medical Limited announced that the U.S. Food and Drug Administration has approved the company’s Investigational Device Exemption application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL® Autologous Cell Harvesting Device for repigmentation of depigmented lesions associated with stable vitiligo..